Wireless Tech Lounge
Looking to stay updated on advancements in wireless connectivity? Learn about Infineon's key offerings here!
How are Infineon's AIROC™ wireless products better than the competition? With the industry's most adopted wireless IP, a benchmark for low-power efficiency, and the industry's best range and performance, our solutions enable smarter IoT devices, connected cars, advanced industrial systems, and next-generation consumer electronics. See why Infineon's AIROC™ wireless solutions are trusted by over 1000 customers!
Infineon's AIROC™ Wi-Fi + Bluetooth® combo solutions are preferred by leading manufacturers of connected products for the digital world. Offering the most advanced features and development tools, optimized power efficiency, and high performance, we enable developers to get IoT products to market fast and with confidence.
Information hub
The Infineon AIROC™ CYW5591x family of single-chip connected microcontrollers (MCUs) offers ultra-low power consumption and supports 1x1 Wi-Fi 6/6E, Bluetooth® Core 5.4, and Matter, making them ideal for Internet-of-Things (IoT) applications. These MCUs feature a 192 MHz Arm Cortex-M33 processor, a wide range of peripherals, and integrated 2.4 GHz and 5/6 GHz transmit power amplifiers and low-noise amplifiers for best-in-class RF performance. The devices support tri-band, dual-band, or single-band operations, with some models also featuring Bluetooth® Core 5.4 with support for LE 1 Mbps, LE 2 Mbps, and LE long range. They also include a power management unit, advanced coexistence hardware mechanisms, and algorithms for optimized simultaneous operation of WLAN and Bluetooth® LE. Additionally, the devices offer various interface options, including SDIO, gSPI, UART, and SPI, and operate over a temperature range of -40°C to +85°C, making them suitable for a wide range of IoT applications.
Learn more about this product here
Resources
Videos
Videos
The Infineon AIROC™ CYW20829 is a high-performance, ultra-low-power and “Secure” MCU + Bluetooth® LE platform, purpose-built for IoT applications. It combines a high-performance microcontroller with Bluetooth® Core 5.4 connectivity, high-performance analog-to-digital conversion audio input, I2S/PCM, CAN, LIN for automotive use cases and other standard communication and timing peripherals. The CYW20829 employs a high level of integration to minimize external components, reducing the device footprint and costs associated with implementing Bluetooth® Low Energy solutions
Learn more about this product here
Resources
Documents
Documents
Migraine is a complex, incurable neurological disease estimated to affect 12% of the global population. Its diagnosis, treatment and management are challenging because migraine affects different people in different ways.
Conventional migraine treatment methods have generally been based on over-the-counter or prescribed medications. However, for an important percentage of those affected by migraine, these medications are either ineffective or lead to disruptive side effects with a negative quality of life (QoL) impact. Hence, alternative and effective methods or devices for migraine care are needed in the market.
Theranica, a digital therapeutics company based in Netanya, Israel, and Bridgewater NJ, USA, has developed Nerivio, a groundbreaking remote electrical neuromodulation (REN) wearable for the treatment of migraine.
Nerivio is an innovative neuromodulation wearable that stimulates nerves in the upper arm through REN. The nerves carry messages to the brain to activate a pain-management response to naturally turn off migraine pain without the need of any medications.
Nerivio is the first FDA-cleared, clinically-proven REN wearable for acute and/or preventive treatment of migraine (indicated for ages 8+ in the United States and 12+ in other countries where it is available). Each Nerivio provides 18 full 45-minute treatments, then can be refilled for additional treatments. The disposable design assures that the patient doesn’t need to remember to keep the battery charged or replace the electrodes while being able to treat just about anywhere. The wearable is placed on the user’s upper arm and worn with an armband during treatments. For its operation, Nerivio uses Bluetooth Low Energy (LE) to connect to a smartphone where the Nerivio application must be installed to control the wearable, to set the treatment intensity, to log activities and monitor migraine patterns, and to enable other beneficial features for the user.
For anyone living with migraine, Nerivio is a valuable treatment option, particularly for the millions of adolescents and children who face limitations in using traditional drug treatments. It has been shown to effectively reduce or prevent migraine attacks and can be used alongside or as an alternative to medication. Nerivio can be worn discreetly while performing normal daily activities. It is safe, effective, and has no systemic side effects.
For the smart health wearables industry, Nerivio is spearheading a new segment of Bluetooth-based therapy devices for idiopathic pain conditions, with great commercial and social potential.
Nerivio’s design demands optimal hardware components to enable
- High resolution, low noise analog to effectively measure electrical signals (e.g. ADC, DAC, opamps)
- High precision signal processing to stimulate and trigger body pain inhibition mechanisms
- Robust Bluetooth connectivity to enable reliable and secure smartphone-based communication and control
- Various interfacing options for user interaction
- System reliability and quality matching therapeutic device needs and expectations
- Low energy, compact size and cost efficiency
Theranica turned to Infineon’s portfolio of Bluetooth LE devices and selected the PSOC 4 BLE MCU for Nerivio and, more recently, the PSOC63 BLE MCU for NerivioInfinity, its next generation migraine treatment solution. They chose PSOC Bluetooth MCUs for the development of their pioneering products because they are capable of delivering
- Fully integrated, single chip solutions supporting all hardware features needed
- Computing and control capabilities matching the needs of the application
- Industry-proven Bluetooth LE connectivity
- Programmable, low noise analog front-end circuitry for bio signal sensing
- Capacitive touch sensing
- Proven track record in wearables for health care applications
“Infineon’s Bluetooth MCUs offered the best analog integration, sound computational power, reliable BLE communication, low power, and compact system real estate. Also, they allowed the flexibility we needed to create safe, state-of-the art wearable devices.” stated Slava Barabash, Theranica’s Vice President of R&D. “Partnering with Infineon proved to be the right choice for Theranica. We received good design documentation, convenient tools and prompt technical support resources that helped to get our designs implemented quickly.”
Theranica envisions Nerivio becoming the leading first-line treatment option for people with migraine to treat and manage the disease, substantially improving their quality of life. Drug-free, meticulously designed with young patients in mind, and with a high safety profile, Nerivio’s FDA clearance was recently expanded to children (ages 8+). Also, Theranica is constantly working on expanding insurance coverage of Nerivio so more patients can have access to drug-free treatment. So far, Nerivio has been gaining significant traction in the market and is becoming an increasingly important smart health wearable in the fight against migraine.
Reach out to Infineon or check out the resources below and learn more about how its Bluetooth LE products can help bring your next disruptive smart health wearable design concept to market successfully.
Documents
Documents
Migraine is a complex, incurable neurological disease estimated to affect 12% of the global population. Its diagnosis, treatment and management are challenging because migraine affects different people in different ways.
Conventional migraine treatment methods have generally been based on over-the-counter or prescribed medications. However, for an important percentage of those affected by migraine, these medications are either ineffective or lead to disruptive side effects with a negative quality of life (QoL) impact. Hence, alternative and effective methods or devices for migraine care are needed in the market.
Theranica, a digital therapeutics company based in Netanya, Israel, and Bridgewater NJ, USA, has developed Nerivio, a groundbreaking remote electrical neuromodulation (REN) wearable for the treatment of migraine.
Nerivio is an innovative neuromodulation wearable that stimulates nerves in the upper arm through REN. The nerves carry messages to the brain to activate a pain-management response to naturally turn off migraine pain without the need of any medications.
Nerivio is the first FDA-cleared, clinically-proven REN wearable for acute and/or preventive treatment of migraine (indicated for ages 8+ in the United States and 12+ in other countries where it is available). Each Nerivio provides 18 full 45-minute treatments, then can be refilled for additional treatments. The disposable design assures that the patient doesn’t need to remember to keep the battery charged or replace the electrodes while being able to treat just about anywhere. The wearable is placed on the user’s upper arm and worn with an armband during treatments. For its operation, Nerivio uses Bluetooth Low Energy (LE) to connect to a smartphone where the Nerivio application must be installed to control the wearable, to set the treatment intensity, to log activities and monitor migraine patterns, and to enable other beneficial features for the user.
For anyone living with migraine, Nerivio is a valuable treatment option, particularly for the millions of adolescents and children who face limitations in using traditional drug treatments. It has been shown to effectively reduce or prevent migraine attacks and can be used alongside or as an alternative to medication. Nerivio can be worn discreetly while performing normal daily activities. It is safe, effective, and has no systemic side effects.
For the smart health wearables industry, Nerivio is spearheading a new segment of Bluetooth-based therapy devices for idiopathic pain conditions, with great commercial and social potential.
Nerivio’s design demands optimal hardware components to enable
- High resolution, low noise analog to effectively measure electrical signals (e.g. ADC, DAC, opamps)
- High precision signal processing to stimulate and trigger body pain inhibition mechanisms
- Robust Bluetooth connectivity to enable reliable and secure smartphone-based communication and control
- Various interfacing options for user interaction
- System reliability and quality matching therapeutic device needs and expectations
- Low energy, compact size and cost efficiency
Theranica turned to Infineon’s portfolio of Bluetooth LE devices and selected the PSOC 4 BLE MCU for Nerivio and, more recently, the PSOC63 BLE MCU for NerivioInfinity, its next generation migraine treatment solution. They chose PSOC Bluetooth MCUs for the development of their pioneering products because they are capable of delivering
- Fully integrated, single chip solutions supporting all hardware features needed
- Computing and control capabilities matching the needs of the application
- Industry-proven Bluetooth LE connectivity
- Programmable, low noise analog front-end circuitry for bio signal sensing
- Capacitive touch sensing
- Proven track record in wearables for health care applications
“Infineon’s Bluetooth MCUs offered the best analog integration, sound computational power, reliable BLE communication, low power, and compact system real estate. Also, they allowed the flexibility we needed to create safe, state-of-the art wearable devices.” stated Slava Barabash, Theranica’s Vice President of R&D. “Partnering with Infineon proved to be the right choice for Theranica. We received good design documentation, convenient tools and prompt technical support resources that helped to get our designs implemented quickly.”
Theranica envisions Nerivio becoming the leading first-line treatment option for people with migraine to treat and manage the disease, substantially improving their quality of life. Drug-free, meticulously designed with young patients in mind, and with a high safety profile, Nerivio’s FDA clearance was recently expanded to children (ages 8+). Also, Theranica is constantly working on expanding insurance coverage of Nerivio so more patients can have access to drug-free treatment. So far, Nerivio has been gaining significant traction in the market and is becoming an increasingly important smart health wearable in the fight against migraine.
Reach out to Infineon or check out the resources below and learn more about how its Bluetooth LE products can help bring your next disruptive smart health wearable design concept to market successfully.
The Infineon AIROC™ CYW5591x family of single-chip connected microcontrollers (MCUs) offers ultra-low power consumption and supports 1x1 Wi-Fi 6/6E, Bluetooth® Core 5.4, and Matter, making them ideal for Internet-of-Things (IoT) applications. These MCUs feature a 192 MHz Arm Cortex-M33 processor, a wide range of peripherals, and integrated 2.4 GHz and 5/6 GHz transmit power amplifiers and low-noise amplifiers for best-in-class RF performance. The devices support tri-band, dual-band, or single-band operations, with some models also featuring Bluetooth® Core 5.4 with support for LE 1 Mbps, LE 2 Mbps, and LE long range. They also include a power management unit, advanced coexistence hardware mechanisms, and algorithms for optimized simultaneous operation of WLAN and Bluetooth® LE. Additionally, the devices offer various interface options, including SDIO, gSPI, UART, and SPI, and operate over a temperature range of -40°C to +85°C, making them suitable for a wide range of IoT applications.
Learn more about this product here
Resources
Videos
Videos
The Infineon AIROC™ CYW20829 is a high-performance, ultra-low-power and “Secure” MCU + Bluetooth® LE platform, purpose-built for IoT applications. It combines a high-performance microcontroller with Bluetooth® Core 5.4 connectivity, high-performance analog-to-digital conversion audio input, I2S/PCM, CAN, LIN for automotive use cases and other standard communication and timing peripherals. The CYW20829 employs a high level of integration to minimize external components, reducing the device footprint and costs associated with implementing Bluetooth® Low Energy solutions
Learn more about this product here
Resources
Documents
Documents
Migraine is a complex, incurable neurological disease estimated to affect 12% of the global population. Its diagnosis, treatment and management are challenging because migraine affects different people in different ways.
Conventional migraine treatment methods have generally been based on over-the-counter or prescribed medications. However, for an important percentage of those affected by migraine, these medications are either ineffective or lead to disruptive side effects with a negative quality of life (QoL) impact. Hence, alternative and effective methods or devices for migraine care are needed in the market.
Theranica, a digital therapeutics company based in Netanya, Israel, and Bridgewater NJ, USA, has developed Nerivio, a groundbreaking remote electrical neuromodulation (REN) wearable for the treatment of migraine.
Nerivio is an innovative neuromodulation wearable that stimulates nerves in the upper arm through REN. The nerves carry messages to the brain to activate a pain-management response to naturally turn off migraine pain without the need of any medications.
Nerivio is the first FDA-cleared, clinically-proven REN wearable for acute and/or preventive treatment of migraine (indicated for ages 8+ in the United States and 12+ in other countries where it is available). Each Nerivio provides 18 full 45-minute treatments, then can be refilled for additional treatments. The disposable design assures that the patient doesn’t need to remember to keep the battery charged or replace the electrodes while being able to treat just about anywhere. The wearable is placed on the user’s upper arm and worn with an armband during treatments. For its operation, Nerivio uses Bluetooth Low Energy (LE) to connect to a smartphone where the Nerivio application must be installed to control the wearable, to set the treatment intensity, to log activities and monitor migraine patterns, and to enable other beneficial features for the user.
For anyone living with migraine, Nerivio is a valuable treatment option, particularly for the millions of adolescents and children who face limitations in using traditional drug treatments. It has been shown to effectively reduce or prevent migraine attacks and can be used alongside or as an alternative to medication. Nerivio can be worn discreetly while performing normal daily activities. It is safe, effective, and has no systemic side effects.
For the smart health wearables industry, Nerivio is spearheading a new segment of Bluetooth-based therapy devices for idiopathic pain conditions, with great commercial and social potential.
Nerivio’s design demands optimal hardware components to enable
- High resolution, low noise analog to effectively measure electrical signals (e.g. ADC, DAC, opamps)
- High precision signal processing to stimulate and trigger body pain inhibition mechanisms
- Robust Bluetooth connectivity to enable reliable and secure smartphone-based communication and control
- Various interfacing options for user interaction
- System reliability and quality matching therapeutic device needs and expectations
- Low energy, compact size and cost efficiency
Theranica turned to Infineon’s portfolio of Bluetooth LE devices and selected the PSOC 4 BLE MCU for Nerivio and, more recently, the PSOC63 BLE MCU for NerivioInfinity, its next generation migraine treatment solution. They chose PSOC Bluetooth MCUs for the development of their pioneering products because they are capable of delivering
- Fully integrated, single chip solutions supporting all hardware features needed
- Computing and control capabilities matching the needs of the application
- Industry-proven Bluetooth LE connectivity
- Programmable, low noise analog front-end circuitry for bio signal sensing
- Capacitive touch sensing
- Proven track record in wearables for health care applications
“Infineon’s Bluetooth MCUs offered the best analog integration, sound computational power, reliable BLE communication, low power, and compact system real estate. Also, they allowed the flexibility we needed to create safe, state-of-the art wearable devices.” stated Slava Barabash, Theranica’s Vice President of R&D. “Partnering with Infineon proved to be the right choice for Theranica. We received good design documentation, convenient tools and prompt technical support resources that helped to get our designs implemented quickly.”
Theranica envisions Nerivio becoming the leading first-line treatment option for people with migraine to treat and manage the disease, substantially improving their quality of life. Drug-free, meticulously designed with young patients in mind, and with a high safety profile, Nerivio’s FDA clearance was recently expanded to children (ages 8+). Also, Theranica is constantly working on expanding insurance coverage of Nerivio so more patients can have access to drug-free treatment. So far, Nerivio has been gaining significant traction in the market and is becoming an increasingly important smart health wearable in the fight against migraine.
Reach out to Infineon or check out the resources below and learn more about how its Bluetooth LE products can help bring your next disruptive smart health wearable design concept to market successfully.
Documents
Documents
Migraine is a complex, incurable neurological disease estimated to affect 12% of the global population. Its diagnosis, treatment and management are challenging because migraine affects different people in different ways.
Conventional migraine treatment methods have generally been based on over-the-counter or prescribed medications. However, for an important percentage of those affected by migraine, these medications are either ineffective or lead to disruptive side effects with a negative quality of life (QoL) impact. Hence, alternative and effective methods or devices for migraine care are needed in the market.
Theranica, a digital therapeutics company based in Netanya, Israel, and Bridgewater NJ, USA, has developed Nerivio, a groundbreaking remote electrical neuromodulation (REN) wearable for the treatment of migraine.
Nerivio is an innovative neuromodulation wearable that stimulates nerves in the upper arm through REN. The nerves carry messages to the brain to activate a pain-management response to naturally turn off migraine pain without the need of any medications.
Nerivio is the first FDA-cleared, clinically-proven REN wearable for acute and/or preventive treatment of migraine (indicated for ages 8+ in the United States and 12+ in other countries where it is available). Each Nerivio provides 18 full 45-minute treatments, then can be refilled for additional treatments. The disposable design assures that the patient doesn’t need to remember to keep the battery charged or replace the electrodes while being able to treat just about anywhere. The wearable is placed on the user’s upper arm and worn with an armband during treatments. For its operation, Nerivio uses Bluetooth Low Energy (LE) to connect to a smartphone where the Nerivio application must be installed to control the wearable, to set the treatment intensity, to log activities and monitor migraine patterns, and to enable other beneficial features for the user.
For anyone living with migraine, Nerivio is a valuable treatment option, particularly for the millions of adolescents and children who face limitations in using traditional drug treatments. It has been shown to effectively reduce or prevent migraine attacks and can be used alongside or as an alternative to medication. Nerivio can be worn discreetly while performing normal daily activities. It is safe, effective, and has no systemic side effects.
For the smart health wearables industry, Nerivio is spearheading a new segment of Bluetooth-based therapy devices for idiopathic pain conditions, with great commercial and social potential.
Nerivio’s design demands optimal hardware components to enable
- High resolution, low noise analog to effectively measure electrical signals (e.g. ADC, DAC, opamps)
- High precision signal processing to stimulate and trigger body pain inhibition mechanisms
- Robust Bluetooth connectivity to enable reliable and secure smartphone-based communication and control
- Various interfacing options for user interaction
- System reliability and quality matching therapeutic device needs and expectations
- Low energy, compact size and cost efficiency
Theranica turned to Infineon’s portfolio of Bluetooth LE devices and selected the PSOC 4 BLE MCU for Nerivio and, more recently, the PSOC63 BLE MCU for NerivioInfinity, its next generation migraine treatment solution. They chose PSOC Bluetooth MCUs for the development of their pioneering products because they are capable of delivering
- Fully integrated, single chip solutions supporting all hardware features needed
- Computing and control capabilities matching the needs of the application
- Industry-proven Bluetooth LE connectivity
- Programmable, low noise analog front-end circuitry for bio signal sensing
- Capacitive touch sensing
- Proven track record in wearables for health care applications
“Infineon’s Bluetooth MCUs offered the best analog integration, sound computational power, reliable BLE communication, low power, and compact system real estate. Also, they allowed the flexibility we needed to create safe, state-of-the art wearable devices.” stated Slava Barabash, Theranica’s Vice President of R&D. “Partnering with Infineon proved to be the right choice for Theranica. We received good design documentation, convenient tools and prompt technical support resources that helped to get our designs implemented quickly.”
Theranica envisions Nerivio becoming the leading first-line treatment option for people with migraine to treat and manage the disease, substantially improving their quality of life. Drug-free, meticulously designed with young patients in mind, and with a high safety profile, Nerivio’s FDA clearance was recently expanded to children (ages 8+). Also, Theranica is constantly working on expanding insurance coverage of Nerivio so more patients can have access to drug-free treatment. So far, Nerivio has been gaining significant traction in the market and is becoming an increasingly important smart health wearable in the fight against migraine.
Reach out to Infineon or check out the resources below and learn more about how its Bluetooth LE products can help bring your next disruptive smart health wearable design concept to market successfully.